Zymeworks Corp - ZYME Net earnings per share for the last four quarters

Official company branding of Zymeworks Corp (ZYME)

Zymeworks Inc. diversifies risks by licensing multispecific antibodies to various partners. Production safety is ensured through strict control of bio-waste disposal. Financial stability is based on payments from pharma behemoths, although R&D costs render cash flow unstable. The relative YoY EPS growth over the last 12 months on this GURU.Markets platform chart reflects profit dynamics, where 180.30 represents the current metric value.

Zymeworks (ZYME) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/14/2026

ZYME (Zymeworks Corp): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart zymeworks.com|ZYME - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Zymeworks Inc|ZYME - Total Company Value
- book value of equity indicators:
Accounting Value per Share Zymeworks|ZYME - Company Book Value|Market Cap to Net Assets Ratio zymeworks.com|ZYME - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Zymeworks Inc.|ZYME - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Zymeworks Biopharmaceuticals|ZYME - Company Debts|Debts to Book Value Zymeworks Inc|ZYME - Company Long-Term Liabilities|Short-Term Indebtedness Zymeworks|Intermediate Liquidity Ratio zymeworks.com
- earnings and market multiples details:
ZYME - Net Profit|Expected Net Income Zymeworks Inc.|ZYME - P/E Multiple|Projected Price to Earnings Ratio Zymeworks Inc|ZYME - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Zymeworks Inc|ZYME - Operating profit EBITDA|Net earnings per share (EPS TTM) Zymeworks|ZYME - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months zymeworks.com|ZYME - Net earnings per share growth this year|Expected net earnings per share growth next year Zymeworks Inc.
- revenue and sales details:
ZYME - Company Sales|Company Expected Revenue zymeworks.com|ZYME - Market Cap to Revenue|Market Cap to Future Revenue Ratio Zymeworks Inc
Initial company analysis:ZYME, zymeworks.com
Mass-produced product of zymeworks.com

This indicator tracks the daily dynamics of rolling trailing twelve-month net earnings per share, enabling the rapid identification of slowing capital growth rates amid inflation. By analyzing the rolling YoY earnings per share change, an investor can assess the commercialization efficiency of Zymeworks Inc. (ZYME) bispecific antibodies, where the peak of zanidatamab clinical trials must transform into a sustainable financial trend.

Direct competitors

Earnings per share for the trailing year IBRX (immunitybio.com)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Arcus Bio|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|SNSE: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months TOVX|GRTS (gritstonebio.com) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Kineta Inc (KA)|Earnings per share for the last twelve months NexImmune Corp|Net earnings per share for the last 12 months Turnstone Biologics Corporation (TSBX)|Net earnings per share (EPS TTM) VCNX|HARP - Net earnings per one share for the last twelve months